David Bradley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
David Bradley has a total of 202 co-authors. Here are the top co-authors by number of shared publications:
- Samuel Klein
Center for Human Nutrition, Washington University School of Medicine, St. Louis, USA
9 shared publications J. Christopher Eagon
8 shared publications- Willa Ann Hsueh
Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Diabetes and Metabolism Research Center, The Ohio State University, Columbus (A.M.B., D.S., X.Y.R., V.P.W., J.L., A.J.S., A.A., C.D.B., D.M., R.G., W.A.H.)
8 shared publications - Alecia Blaszczak
Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Diabetes and Metabolism Research Center, The Ohio State University, Columbus (A.M.B., D.S., X.Y.R., V.P.W., J.L., A.J.S., A.A., C.D.B., D.M., R.G., W.A.H.)
7 shared publications - Faidon Magkos
Department of Nutrition, Exercise and Sports, University of Copenhagen, Frederiksberg, Denmark
7 shared publications - Bruce W. Patterson
Center for Human Nutrition, Washington University School of Medicine, St. Louis, Missouri, USA
6 shared publications
Latest Publications
- 1 November 2026
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 46 (11)
Adipose Tissue Immunosuppressive T Cells Regulate Atherosclerosis Development and Liver Fat Accumulation in Obesity
BACKGROUND: Obesity is associated with a loss of anti-inflammatory regulatory T cells (Tregs) in adipose tissue (AT), resulting in systemic inflammation. The adipocyte is a central modulator of CD4+T-cell subpopulations via antigen presentation through the MHCII (major histocompatibility complex class II). However, the role of adipocyte-induced AT inflammation due to changes in AT Tregs in obesity-related complications, such as atherosclerosis and metabolic-dysfunction-associated fatty liver disease (MAFLD), remains unknown. METHODS: Ldlr (low-density lipoprotein receptor) −/− knockout mice were crossed with adipocyte-specific MHCII knockout (aMHCll [adipocyte MHCII] −/− ) mice to study the effects of AT T-cell changes on atherosclerosis and MAFLD. Metabolic differences, atherosclerotic lesions, liver fat accumulation, and inflammation in adipose, splenic, aortic, and liver tissue were measured in 1-year-old aMHCll −/− Ldlr −/− mice fed a Western high-fat diet for 12 weeks. We used 1-year-old mice because, unlike young mice, they develop markedly accelerated atherosclerosis like humans. RESULTS: Loss of MHCII signaling in adipocytes prevented the obesity-mediated loss of AT Tregs, resulting in decreased insulin resistance, atherosclerosis, and MAFLD. In contrast, depletion of AT Tregs via IL (interleukin)-33 receptor–targeted immunotherapy with ST2 (suppression of tumorigenicity 2) reversed these improvements in Western high-fat diet–fed, 1-year-old aMHCll −/− Ldlr −/− mice, whereas increasing AT Tregs with IL-33 recombinant protein promoted similar beneficial effects as in aMHCll −/− Ldlr −/− mice. Because there were no alterations in splenic Tregs, these differences in atherosclerosis and MAFLD were AT Treg-mediated, independent of peripheral Tregs. Amelioration of insulin resistance, atherosclerosis, and MAFLD was diet- and adipocyte-dependent, as a low-fat, Western diet administered to 1-year-old aMHCll −/− Ldlr −/− mice and myeloid-adipo–specific MHCII knockout mice (m-aMHCll [myeloid-adipocyte MHCII] −/− ) ingesting a Western high-fat diet, had no effect on disease progression. CONCLUSIONS: These results suggest that AT immunosuppressive T cells play a pivotal role in regulating both atherosclerosis development and liver fat accumulation in obesity.
- 1 November 2026
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 46 (11)
Adipose Tissue Immunosuppressive T Cells Regulate Atherosclerosis Development and Liver Fat Accumulation in Obesity
BACKGROUND: Obesity is associated with a loss of anti-inflammatory regulatory T cells (Tregs) in adipose tissue (AT), resulting in systemic inflammation. The adipocyte is a central modulator of CD4+T-cell subpopulations via antigen presentation through the MHCII (major histocompatibility complex class II). However, the role of adipocyte-induced AT inflammation due to changes in AT Tregs in obesity-related complications, such as atherosclerosis and metabolic-dysfunction-associated fatty liver disease (MAFLD), remains unknown. METHODS: Ldlr (low-density lipoprotein receptor) −/− knockout mice were crossed with adipocyte-specific MHCII knockout (aMHCll [adipocyte MHCII] −/− ) mice to study the effects of AT T-cell changes on atherosclerosis and MAFLD. Metabolic differences, atherosclerotic lesions, liver fat accumulation, and inflammation in adipose, splenic, aortic, and liver tissue were measured in 1-year-old aMHCll −/− Ldlr −/− mice fed a Western high-fat diet for 12 weeks. We used 1-year-old mice because, unlike young mice, they develop markedly accelerated atherosclerosis like humans. RESULTS: Loss of MHCII signaling in adipocytes prevented the obesity-mediated loss of AT Tregs, resulting in decreased insulin resistance, atherosclerosis, and MAFLD. In contrast, depletion of AT Tregs via IL (interleukin)-33 receptor–targeted immunotherapy with ST2 (suppression of tumorigenicity 2) reversed these improvements in Western high-fat diet–fed, 1-year-old aMHCll −/− Ldlr −/− mice, whereas increasing AT Tregs with IL-33 recombinant protein promoted similar beneficial effects as in aMHCll −/− Ldlr −/− mice. Because there were no alterations in splenic Tregs, these differences in atherosclerosis and MAFLD were AT Treg-mediated, independent of peripheral Tregs. Amelioration of insulin resistance, atherosclerosis, and MAFLD was diet- and adipocyte-dependent, as a low-fat, Western diet administered to 1-year-old aMHCll −/− Ldlr −/− mice and myeloid-adipo–specific MHCII knockout mice (m-aMHCll [myeloid-adipocyte MHCII] −/− ) ingesting a Western high-fat diet, had no effect on disease progression. CONCLUSIONS: These results suggest that AT immunosuppressive T cells play a pivotal role in regulating both atherosclerosis development and liver fat accumulation in obesity.
- Open Access
- 1 February 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (2)
Multidisciplinary clinic model enhances liver and metabolic health outcomes in adults with MASH
Export
- 1 February 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (2)
Open AccessMultidisciplinary clinic model enhances liver and metabolic health outcomes in adults with MASH
Export
- Open Access
- 12 February 2024
- Published by Annual Reviews in Annual Review of Physiology
- Vol. 86 (1) , 199-223
Orchestration of the Adipose Tissue Immune Landscape by Adipocytes
Obesity is epidemic and of great concern because of its comorbid and costly inflammatory-driven complications. Extensive investigations in mice have elucidated highly coordinated, well-balanced interactions between adipocytes and immune cells in adipose tissue that maintain normal systemic metabolism in the lean state, while in obesity, proinflammatory changes occur in nearly all adipose tissue immune cells. Many of these changes are instigated by adipocytes. However, less is known about obesity-induced adipose-tissue immune cell alterations in humans. Upon high-fat diet feeding, the adipocyte changes its well-known function as a metabolic cell to assume the role of an immune cell, orchestrating proinflammatory changes that escalate inflammation and progress during obesity. This transformation is particularly prominent in humans. In this review, we ( a) highlight a leading and early role for adipocytes in promulgating inflammation, ( b) discuss immune cell changes and the time course of these changes (comparing humans and mice when possible), and ( c) note how reversing proinflammatory changes in most types of immune cells, including adipocytes, rescues adipose tissue from inflammation and obese mice from insulin resistance.
- 12 February 2024
- Published by Annual Reviews in Annual Review of Physiology
- Vol. 86 (1) , 199-223
Open AccessOrchestration of the Adipose Tissue Immune Landscape by Adipocytes
Obesity is epidemic and of great concern because of its comorbid and costly inflammatory-driven complications. Extensive investigations in mice have elucidated highly coordinated, well-balanced interactions between adipocytes and immune cells in adipose tissue that maintain normal systemic metabolism in the lean state, while in obesity, proinflammatory changes occur in nearly all adipose tissue immune cells. Many of these changes are instigated by adipocytes. However, less is known about obesity-induced adipose-tissue immune cell alterations in humans. Upon high-fat diet feeding, the adipocyte changes its well-known function as a metabolic cell to assume the role of an immune cell, orchestrating proinflammatory changes that escalate inflammation and progress during obesity. This transformation is particularly prominent in humans. In this review, we ( a) highlight a leading and early role for adipocytes in promulgating inflammation, ( b) discuss immune cell changes and the time course of these changes (comparing humans and mice when possible), and ( c) note how reversing proinflammatory changes in most types of immune cells, including adipocytes, rescues adipose tissue from inflammation and obese mice from insulin resistance.
- Open Access
- 22 June 2023
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 8 (12)
β Cell function after Roux-en-Y gastric bypass surgery or reduced energy intake alone in people with obesity
Background: The effects of diet-induced weight loss (WL) and WL after Roux-en-Y gastric bypass (RYGB) surgery on β cell function (BCF) are unclear because of conflicting results from different studies, presumably because of differences in the methods used to measure BCF, the amount of WL between treatment groups, and baseline BCF. We evaluated the effect of WL after RYGB surgery or reduced energy intake alone on BCF in people with obesity with and without type 2 diabetes. Methods: BCF (insulin secretion in relationship to plasma glucose) was assessed before and after glucose or mixed-meal ingestion before and after (a) progressive amounts (6%, 11%, 16%) of WL induced by a low-calorie diet (LCD) in people with obesity without diabetes, (b) ~20% WL after RYGB surgery or laparoscopic adjustable gastric banding (LAGB) in people with obesity without diabetes, and (c) ~20% WL after RYGB surgery or LCD alone in people with obesity and diabetes. Results: Diet-induced progressive WL in people without diabetes progressively decreased BCF. Marked WL after LAGB or RYGB in people without diabetes did not alter BCF. Marked WL after LCD or RYGB in people with diabetes markedly increased BCF, without a difference between groups. Conclusion: Marked WL increases BCF in people with obesity and diabetes but not in people with obesity without diabetes. The effect of RYGB-induced WL on BCF is not different from the effect of matched WL after LAGB or LCD alone. trial registration: NCT00981500, NCT02207777, NCT01299519. Funding: NIH grants R01 DK037948, P30 DK056341, P30 DK020579, UL1 TR002345.
- 22 June 2023
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 8 (12)
Open Accessβ Cell function after Roux-en-Y gastric bypass surgery or reduced energy intake alone in people with obesity
Background: The effects of diet-induced weight loss (WL) and WL after Roux-en-Y gastric bypass (RYGB) surgery on β cell function (BCF) are unclear because of conflicting results from different studies, presumably because of differences in the methods used to measure BCF, the amount of WL between treatment groups, and baseline BCF. We evaluated the effect of WL after RYGB surgery or reduced energy intake alone on BCF in people with obesity with and without type 2 diabetes. Methods: BCF (insulin secretion in relationship to plasma glucose) was assessed before and after glucose or mixed-meal ingestion before and after (a) progressive amounts (6%, 11%, 16%) of WL induced by a low-calorie diet (LCD) in people with obesity without diabetes, (b) ~20% WL after RYGB surgery or laparoscopic adjustable gastric banding (LAGB) in people with obesity without diabetes, and (c) ~20% WL after RYGB surgery or LCD alone in people with obesity and diabetes. Results: Diet-induced progressive WL in people without diabetes progressively decreased BCF. Marked WL after LAGB or RYGB in people without diabetes did not alter BCF. Marked WL after LCD or RYGB in people with diabetes markedly increased BCF, without a difference between groups. Conclusion: Marked WL increases BCF in people with obesity and diabetes but not in people with obesity without diabetes. The effect of RYGB-induced WL on BCF is not different from the effect of matched WL after LAGB or LCD alone. trial registration: NCT00981500, NCT02207777, NCT01299519. Funding: NIH grants R01 DK037948, P30 DK056341, P30 DK020579, UL1 TR002345.
- Open Access
- 24 September 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-12
Interferon gamma mediates the reduction of adipose tissue regulatory T cells in human obesity
Decreased adipose tissue regulatory T cells contribute to insulin resistance in obese mice, however, little is known about the mechanisms regulating adipose tissue regulatory T cells numbers in humans. Here we obtain adipose tissue from obese and lean volunteers. Regulatory T cell abundance is lower in obese vs. lean visceral and subcutaneous adipose tissue and associates with reduced insulin sensitivity and altered adipocyte metabolic gene expression. Regulatory T cells numbers decline following high-fat diet induction in lean volunteers. We see alteration in major histocompatibility complex II pathway in adipocytes from obese patients and after high fat ingestion, which increases T helper 1 cell numbers and decreases regulatory T cell differentiation. We also observe increased expression of inhibitory co-receptors including programmed cell death protein 1 and OX40 in visceral adipose tissue regulatory T cells from patients with obesity. In human obesity, these global effects of interferon gamma to reduce regulatory T cells and diminish their function appear to instigate adipose inflammation and suppress adipocyte metabolism, leading to insulin resistance.
- 24 September 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-12
Open AccessInterferon gamma mediates the reduction of adipose tissue regulatory T cells in human obesity
Decreased adipose tissue regulatory T cells contribute to insulin resistance in obese mice, however, little is known about the mechanisms regulating adipose tissue regulatory T cells numbers in humans. Here we obtain adipose tissue from obese and lean volunteers. Regulatory T cell abundance is lower in obese vs. lean visceral and subcutaneous adipose tissue and associates with reduced insulin sensitivity and altered adipocyte metabolic gene expression. Regulatory T cells numbers decline following high-fat diet induction in lean volunteers. We see alteration in major histocompatibility complex II pathway in adipocytes from obese patients and after high fat ingestion, which increases T helper 1 cell numbers and decreases regulatory T cell differentiation. We also observe increased expression of inhibitory co-receptors including programmed cell death protein 1 and OX40 in visceral adipose tissue regulatory T cells from patients with obesity. In human obesity, these global effects of interferon gamma to reduce regulatory T cells and diminish their function appear to instigate adipose inflammation and suppress adipocyte metabolism, leading to insulin resistance.
- Open Access
- 26 July 2022
- Published by JMIR Publications Inc. in JMIR Diabetes
- Vol. 7 (3) , e33401
Effectiveness of a Diabetes-Focused Electronic Discharge Order Set and Postdischarge Nursing Support Among Poorly Controlled Hospitalized Patients: Randomized Controlled Trial
Background: Although the use of electronic order sets has become standard practice for inpatient diabetes management, there is limited decision support at discharge. Objective: In this study, we assessed whether an electronic discharge order set (DOS) plus nurse follow-up calls improve discharge orders and postdischarge outcomes among hospitalized patients with type 2 diabetes mellitus. Methods: This was a randomized, open-label, single center study that compared an electronic DOS and nurse phone calls to enhanced standard care (ESC) in hospitalized insulin-requiring patients with type 2 diabetes mellitus. The primary outcome was change in glycated hemoglobin (HbA1c) level at 24 weeks after discharge. The secondary outcomes included the completeness and accuracy of discharge prescriptions related to diabetes. Results: This study was stopped early because of feasibility concerns related to the long-term follow-up. However, 158 participants were enrolled (DOS: n=82; ESC: n=76), of whom 155 had discharge data. The DOS group had a greater frequency of prescriptions for bolus insulin (78% vs 44%; P=.01), needles or syringes (95% vs 63%; P=.03), and glucometers (86% vs 36%; P<.001). The clarity of the orders was similar. HbA1c data were available for 54 participants in each arm at 12 weeks and for 44 and 45 participants in the DOS and ESC arms, respectively, at 24 weeks. The unadjusted difference in change in HbA1c level (DOS – ESC) was −0.6% (SD 0.4%; P=.18) at 12 weeks and −1.1% (SD 0.4%; P=.01) at 24 weeks. The adjusted difference in change in HbA1c level was −0.5% (SD 0.4%; P=.20) at 12 weeks and −0.7% (SD 0.4%; P=.09) at 24 weeks. The achievement of the individualized HbA1c target was greater in the DOS group at 12 weeks but not at 24 weeks. Conclusions: An intervention that included a DOS plus a postdischarge nurse phone call resulted in more complete discharge prescriptions. The assessment of postdischarge outcomes was limited, owing to the loss of the long-term follow-up, but it suggested a possible benefit in glucose control. Trial Registration: ClinicalTrials.gov NCT03455985; https://clinicaltrials.gov/ct2/show/NCT03455985
- 26 July 2022
- Published by JMIR Publications Inc. in JMIR Diabetes
- Vol. 7 (3) , e33401
Open AccessEffectiveness of a Diabetes-Focused Electronic Discharge Order Set and Postdischarge Nursing Support Among Poorly Controlled Hospitalized Patients: Randomized Controlled Trial
Background: Although the use of electronic order sets has become standard practice for inpatient diabetes management, there is limited decision support at discharge. Objective: In this study, we assessed whether an electronic discharge order set (DOS) plus nurse follow-up calls improve discharge orders and postdischarge outcomes among hospitalized patients with type 2 diabetes mellitus. Methods: This was a randomized, open-label, single center study that compared an electronic DOS and nurse phone calls to enhanced standard care (ESC) in hospitalized insulin-requiring patients with type 2 diabetes mellitus. The primary outcome was change in glycated hemoglobin (HbA1c) level at 24 weeks after discharge. The secondary outcomes included the completeness and accuracy of discharge prescriptions related to diabetes. Results: This study was stopped early because of feasibility concerns related to the long-term follow-up. However, 158 participants were enrolled (DOS: n=82; ESC: n=76), of whom 155 had discharge data. The DOS group had a greater frequency of prescriptions for bolus insulin (78% vs 44%; P=.01), needles or syringes (95% vs 63%; P=.03), and glucometers (86% vs 36%; P<.001). The clarity of the orders was similar. HbA1c data were available for 54 participants in each arm at 12 weeks and for 44 and 45 participants in the DOS and ESC arms, respectively, at 24 weeks. The unadjusted difference in change in HbA1c level (DOS – ESC) was −0.6% (SD 0.4%; P=.18) at 12 weeks and −1.1% (SD 0.4%; P=.01) at 24 weeks. The adjusted difference in change in HbA1c level was −0.5% (SD 0.4%; P=.20) at 12 weeks and −0.7% (SD 0.4%; P=.09) at 24 weeks. The achievement of the individualized HbA1c target was greater in the DOS group at 12 weeks but not at 24 weeks. Conclusions: An intervention that included a DOS plus a postdischarge nurse phone call resulted in more complete discharge prescriptions. The assessment of postdischarge outcomes was limited, owing to the loss of the long-term follow-up, but it suggested a possible benefit in glucose control. Trial Registration: ClinicalTrials.gov NCT03455985; https://clinicaltrials.gov/ct2/show/NCT03455985
- Open Access
- 23 December 2021
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12, 827281
Editorial: The Immunomodulatory Roles of Adipocytes
Editorial: The Immunomodulatory Roles of Adipocytes
- 23 December 2021
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12, 827281
Open AccessEditorial: The Immunomodulatory Roles of Adipocytes
Editorial: The Immunomodulatory Roles of Adipocytes
- Open Access
- 25 February 2021
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12
Clusterin and Its Role in Insulin Resistance and the Cardiometabolic Syndrome
The cardiometabolic syndrome involves a clustering of metabolic and cardiovascular factors which increase the risk of patients developing both Type 2 Diabetes Mellitus and cardio/cerebrovascular disease. Although the mechanistic underpinnings of this link remain uncertain, key factors include insulin resistance, excess visceral adiposity, atherogenic dyslipidemia, and endothelial dysfunction. Of these, a state of resistance to insulin action in overweight/obese patients appears to be central to the pathophysiologic process. Given the increasing prevalence of obesity-related Type 2 Diabetes, coupled with the fact that cardiovascular disease is the number one cause of mortality in this patient population, a more thorough understanding of the cardiometabolic syndrome and potential options to mitigate its risk is imperative. Inherent in the pathogenesis of insulin resistance is an underlying state of chronic inflammation, at least partly in response to excess adiposity. Within obese adipose tissue, an immunomodulatory shift occurs, involving a preponderance of pro-inflammatory immune cells and cytokines/adipokines, along with antigen presentation by adipocytes. Therefore, various adipokines differentially expressed by obese adipocytes may have a significant effect on cardiometabolism. Clusterin is a molecular chaperone that is widely produced by many tissues throughout the body, but is also preferentially overexpressed by obese compared lean adipocytes and relates strongly to multiple components of the cardiometabolic syndrome. Herein, we summarize the known and potential roles of circulating and adipocyte-specific clusterin in cardiometabolism and discuss potential further investigations to determine if clusterin is a viable target to attenuate both metabolic and cardiovascular disease.
- 25 February 2021
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12
Open AccessClusterin and Its Role in Insulin Resistance and the Cardiometabolic Syndrome
The cardiometabolic syndrome involves a clustering of metabolic and cardiovascular factors which increase the risk of patients developing both Type 2 Diabetes Mellitus and cardio/cerebrovascular disease. Although the mechanistic underpinnings of this link remain uncertain, key factors include insulin resistance, excess visceral adiposity, atherogenic dyslipidemia, and endothelial dysfunction. Of these, a state of resistance to insulin action in overweight/obese patients appears to be central to the pathophysiologic process. Given the increasing prevalence of obesity-related Type 2 Diabetes, coupled with the fact that cardiovascular disease is the number one cause of mortality in this patient population, a more thorough understanding of the cardiometabolic syndrome and potential options to mitigate its risk is imperative. Inherent in the pathogenesis of insulin resistance is an underlying state of chronic inflammation, at least partly in response to excess adiposity. Within obese adipose tissue, an immunomodulatory shift occurs, involving a preponderance of pro-inflammatory immune cells and cytokines/adipokines, along with antigen presentation by adipocytes. Therefore, various adipokines differentially expressed by obese adipocytes may have a significant effect on cardiometabolism. Clusterin is a molecular chaperone that is widely produced by many tissues throughout the body, but is also preferentially overexpressed by obese compared lean adipocytes and relates strongly to multiple components of the cardiometabolic syndrome. Herein, we summarize the known and potential roles of circulating and adipocyte-specific clusterin in cardiometabolism and discuss potential further investigations to determine if clusterin is a viable target to attenuate both metabolic and cardiovascular disease.
- 2 February 2021
- Published by Springer Nature
- Vol. 1278, 125-139
Adipose Tissue T Regulatory Cells: Implications for Health and Disease
Obesity dramatically increases the risk of numerous conditions, including type 2 diabetes mellitus and other components of the metabolic syndrome. Pro-inflammatory changes that occur in adipose tissue are critical to the pathogenesis of these obesity-induced complications. Adipose tissue is one of the body’s largest endocrine organs, and the cells that comprise the adipose tissue immunoenvironment secrete multiple factors (including adipokines and cytokines) that impact systemic metabolism. In particular, immunosuppressive regulatory T cells (Tregs) decline in obesity, partly in response to its complex interaction with adipocytes, and this decline contributes to disruption of the typical homeostasis observed in lean adipose tissue. Although the regulation of Treg differentiation, function, and enrichment is incompletely understood, factors including various cell-surface co-stimulatory molecules, certain lipid species, and cytokines such as PPARγ, adiponectin, and leptin are important mediators. It is also clear that there may be depot-specific differences in Tregs, rendering adipose tissue Tregs distinct from lymphoid or circulating Tregs, with implications on maintenance and functionality. While most of these findings are derived from studies in murine models, comparatively little is known about the human adipose tissue Treg signature, which requires further investigation.
- 2 February 2021
- Published by Springer Nature
- Vol. 1278, 125-139
Adipose Tissue T Regulatory Cells: Implications for Health and Disease
Obesity dramatically increases the risk of numerous conditions, including type 2 diabetes mellitus and other components of the metabolic syndrome. Pro-inflammatory changes that occur in adipose tissue are critical to the pathogenesis of these obesity-induced complications. Adipose tissue is one of the body’s largest endocrine organs, and the cells that comprise the adipose tissue immunoenvironment secrete multiple factors (including adipokines and cytokines) that impact systemic metabolism. In particular, immunosuppressive regulatory T cells (Tregs) decline in obesity, partly in response to its complex interaction with adipocytes, and this decline contributes to disruption of the typical homeostasis observed in lean adipose tissue. Although the regulation of Treg differentiation, function, and enrichment is incompletely understood, factors including various cell-surface co-stimulatory molecules, certain lipid species, and cytokines such as PPARγ, adiponectin, and leptin are important mediators. It is also clear that there may be depot-specific differences in Tregs, rendering adipose tissue Tregs distinct from lymphoid or circulating Tregs, with implications on maintenance and functionality. While most of these findings are derived from studies in murine models, comparatively little is known about the human adipose tissue Treg signature, which requires further investigation.
- Open Access
- 29 January 2021
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 106 (5) , e2370-e2372
The Intriguing Intersection of Type 2 Diabetes, Obesity-Related Insulin Resistance, and Osteoarthritis
Osteoarthritis (OA) is characterized by degeneration of hyaline joint cartilage, hypertrophic changes to the joint capsule, and damage to underlying bone with s
- 29 January 2021
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 106 (5) , e2370-e2372
Open AccessThe Intriguing Intersection of Type 2 Diabetes, Obesity-Related Insulin Resistance, and Osteoarthritis
Osteoarthritis (OA) is characterized by degeneration of hyaline joint cartilage, hypertrophic changes to the joint capsule, and damage to underlying bone with s